Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

Returns on capital

Faeth Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-113.4%

avg -49.3%

ROIC

-110.9%

avg 1343.1%

ROA

-92.1%

avg -305.4%

Analysis

ROA is currently the strongest return metric at -92.1% versus its period average of -305.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Christopher Gerry

General Counsel & SecretaryUSD 416.04K46220.00K0.85%

Josiah Craver

Senior Vice President of Finance, Principal Financial Officer & Principal Accounting OfficerUSD 391.15K—30.82K0.12%

Benjamin Hopkins

Scientific Co-Founder————

Gregory J. Hannon

Scientific Co-Founder————

Lewis clayton Cantley

Scientific Co-Founder—77——

Scott W. Lowe

Scientific Co-Founder————

Siddhartha Mukherjee DPHIL

Scientific Co-Founder—55——

Simon Knott

Scientific Co-Founder————

Karen H. Vousden

Scientific Co-Founder & Director—6842.63K0.17%

Anand Parikh

CEO, President & Chair—40——

Oliver Maddocks

Co-Founder & Chief Scientific Officer————

Compensation is shown in the reported currency; data updated Nov 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

49

$2.53M

Sells

45

$2.28M

Net Transaction Value

+$250,415.94

Net buying

Most Active

MILLENNIUM MANAGEMENT LLC

51 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 1, 26

STEPHENSON BRIAN C

Indirect

Buy$14.5K
Jul 1, 26

STEPHENSON BRIAN C

Indirect

Buy$103K
Jun 30, 26

STEPHENSON BRIAN C

Indirect

Buy$39.1K
Jun 30, 26

STEPHENSON BRIAN C

Indirect

Buy$43.8K
Jun 30, 26

STEPHENSON BRIAN C

Indirect

Buy$106.3K
Jun 29, 26

STEPHENSON BRIAN C

Indirect

Buy$19.4K
Jun 26, 26

STEPHENSON BRIAN C

Indirect

Buy$34.7K
Jun 26, 26

STEPHENSON BRIAN C

Indirect

Buy$13.7K
Jun 26, 26

STEPHENSON BRIAN C

Indirect

Buy$2.6K
Jun 26, 26

STEPHENSON BRIAN C

Indirect

Buy$104.9K

1–10 of 94

Summary

Insiders reported 49 buys worth $2.53M and 45 sells worth $2.28M over the last 12 months. That adds up to net buying of $250,415.94. MILLENNIUM MANAGEMENT LLC was the most active insider with 51 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Faeth Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about FTH's management, answered from reported figures.

Who manages FTH?

Faeth Therapeutics, Inc. (FTH) lists 11 active executives. The top listed executive is Benjamin Hopkins, Scientific Co-Founder.

Are FTH insiders buying or selling?

Recent insider activity shows net buying of $56.18M.